You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 27 Next »

Project Scope 

The goals of this project are to obtain broad industry and CRO feedback on the current publicly available OCE/OOD standard safety data request (found at: https://www.fda.gov/media/133252/download) and assist with the development of resources to assist sponsors with implementation of these data specifications.

There is tremendous variability and inconsistency in the use of the CDISC ADaM data standard in safety datasets for oncology NDA/BLA applications submitted to FDA. This variability leads to inefficiency in review for the FDA and multiple information requests to applicants during the course of the review to resolve inconsistencies in analyses between FDA and applicants. The Oncology Centre of Excellence (OCE)/Office of Oncologic Diseases (OOD) has developed a pilot standard safety data request for datasets submitted with NDA/BLA applications and instructions for conducting select safety analyses to create a common set of data elements with common use of these variables for safety analyses. The stakeholders include FDA reviewers and analysts, industry, CROs, and software developers.

Project LeadsEmail
Chris Pricechris.price@phuse.global 
Meredith Chukmeredith.chuk@fda.hhs.gov
Peter Schotland

peter.schotland@fda.hhs.gov

Wendy Dobson (PHUSE Project Manager)

wendy@phuse.global

DeliverablesTimelines
Feedback on publicly available OCE/OOD safety data requestQ2
Development of basic resources for sponsors to assist implementation (e.g. CRF design to collect relevant data and linkages for adverse events and dataset preparation for laboratory analyses or other resources requested or found to be needed during the feedback process)Q2

CURRENT STATUS Q12021

This project kicked off in March and is working through the OCE/OOD standard safety data request. The first round has completed and the FDA are currently reviewing. The team will take a short break whilst the review is underway and then reconvene for Phase II

Project MembersOrganisation
Bhupendra MistryRoche
Cathy BezekAstellas
Cindy MarabottiSanofi
Diane WoldCDISC
Gopi VegesnaAstellas
Greg Ball Merck
Gregory PurnsleyPfizer
Hitesh ThackerCovance
Hong QiMerck
Joy GeMerck
Karen YingGSK
Ken MaahsJanssen Research & Development
Lihui Deng BMS 
Lindsay McLeanPharstar
Marleen NijsJanssen Research & Development

Matt Smith 

Pfizer
Project MembersOrganisation

Maxime Rouch 

Sanofi
Paul FrostGEM Programming
Pavan KumarGSK
Peter Bonata BayerBayer
Srinivas KolamuriNovartis
Suriaya WalshAstraZeneca
Suwen LiRoche

Tatiana Sotingco

Janssen Research & Development
Tim YoungGSK
Venkata Rajesh DatlaGenmab
Vishnu DabbiruGSK
Wenyun JiAbbVie
Whitney BoeckelGSK
William PaloAbbVie
  • No labels